Pertuzumab, a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
Cat.No
A024
Name
Pertuzumab
Chemical Properties
CAS
380610-27-5
Synonyms
Pertuzumab;Pertuzumab [INN]; 2C4; Omnitarg; Omnitarg, 2C4; UNII-K16AIQ8CTM; rhuMAb 2C4; Immunoglobulin G1, anti-(human v (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 kappa-chain, dimer
pH value
Corresponds to reference standard： PASS
Non-reduced CE-SDS
98.5%
SEC-HPLC
99.1%
Isoelectric Point
Corresponds to reference standard
Bacterial Endotoxins Test
＜1 EU/ml
Residual Proteins of Host Cell
Exogenous Residual DNA
＜1 pg/mg
Residual protein A
＜1 ng/mg
Biological Activity
Compared with standard, the range ofbiological activity is 103%
Osmolality
Corresponds to reference standard: PASS
Peptide mapping
Corresponds to reference standard: PASS
N-terminal sequence
Corresponds to reference standard:PASS
References
[1]. Nahta R, et al. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survivalof breast cancer cells. Cancer Res. 2004 Apr 1;64(7):2343-6.
[2]. Scheuer W, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009 Dec 15;69(24):9330-6.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
